BenQ Medical Technology (ROCO:4116) ROCE %: 13.81% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4116 BenQ Medical Technology Corp ROCO:4116
81 GF Score
Price NT$38.60
GF Value NT$62.38
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is BenQ Medical Technology ROCE %?

BenQ Medical Technology ROCO:4116 +0.39% 81 ROCE % is 13.81% as of Dec. 2025. GuruFocus rates ROCO:4116 with a GF Score™ of 81/100 and a GF Value™ of NT$62.38 (Significantly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BenQ Medical Technology's annualized ROCE % for the quarter that ended in Dec. 2025 was 13.81%.

BenQ Medical Technology  (ROCO:4116) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BenQ Medical Technology ROCE % Related Terms

BenQ Medical Technology ROCE % Historical Data

* Premium members only.

The historical data trend for BenQ Medical Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BenQ Medical Technology ROCE % Chart

BenQ Medical Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 19.51 12.19 10.63 11.36

BenQ Medical Technology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.91 9.30 8.58 13.82 13.81
ROCO:4116
81GF Score
BenQ Medical Technology Corp ROCO:4116
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BenQ Medical Technology ROCE % Calculation

BenQ Medical Technology's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=379.2/( ( (5273.81 - 1768.178) + (5450.611 - 2277.276) )/ 2 )
=379.2/( (3505.632+3173.335)/ 2 )
=379.2/3339.4835
=11.36 %

BenQ Medical Technology's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=448.328/( ( (5239.588 - 1919.293) + (5450.611 - 2277.276) )/ 2 )
=448.328/( ( 3320.295 + 3173.335 )/ 2 )
=448.328/3246.815
=13.81 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 13.81% mean?
BenQ Medical Technology (ROCO:4116) has a ROCE % of 13.81% as of Dec. 2025.
Is BenQ Medical Technology's ROCE % too high?
BenQ Medical Technology's current ROCE % is 13.81%. The Medical Devices & Instruments industry median ROCE % is 2.26. BenQ Medical Technology's value of 13.81% is 511.1% above this industry median. Overall, BenQ Medical Technology has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's ROCE % compare to ISRG and BDX?
BenQ Medical Technology's ROCE % of 13.81% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.26. BenQ Medical Technology's value of 13.81% is 511.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.26, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BenQ Medical Technology's current ROCE % of 13.81% is 511.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BenQ Medical Technology's current ROCE % is 13.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$62.38, compared to a current price of NT$38.60 — trading 38.1% below its estimated fair value. The current ROCE % is 13.81% and 511.1% above the Medical Devices & Instruments industry median of 2.26. BenQ Medical Technology's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current ROCE % is 13.81% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?

Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued. The current stock price of NT$38.60 is trading 38.1% below its estimated GF Value™ of NT$62.38. GuruFocus considers BenQ Medical Technology to be Significantly Undervalued.

Key valuation signals for ROCO:4116:

  • ROCE %: 13.81%
  • GF Value™: NT$62.38 vs. price of NT$38.60 (38.1% below fair value)
  • GF Score™: 81/100 with 6 warning signs
  • Industry Position: 511.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BenQ Medical Technology Business Description

Address No.46, Zhouzi Street, 7th Floor, Neihu District, Taipei, TWN, 11493
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
81GF Score

Get the complete analysis for ROCO:4116

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.60
Price
NT$62.38
GF Value